AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02497937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745
Description: GSK2798745 will be supplied as granule filled capsule with unit dose strength of 2.4 mg to be administered orally with 240 mL water.
Study NCT02497937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be supplied as blend filled capsule to be administered orally with 240 mL water.
Study NCT00671801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 200 mg/m\^2 by vein over 90 minutes once every 2 weeks on days 1 and 15.
Study NCT00671801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given orally at escalating doses beginning 7.5 mg/day on Cycle 1 Days 1-21 and 10 mg/day on Cycle 2 Days 1-21.
Study NCT04110886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK21542
Description: Single dose, injection, starting dose of 0.2ug escalating up to 20ug
Study NCT04110886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose, injection matching placebo
Study NCT01564992 — intervention group
Intervention type: OTHER
Intervention: Identification of genes
Description: Identification of genes which polymorphism or haplotype is associated with a complication of Parkinson disease, directly or with the interaction of treatment.
Study NCT03941145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced-Exertion High-Intensity Interval Training (REHIT)
Description: REHIT is a type of Sprint Interval Training (SIT) that has been shown to be efficacious at improving maximal aerobic capacity using a minimal volume of exercise.
Study NCT02677597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin Combined With S-1
Study NCT02677597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin Combined With Paclitaxel
Study NCT01492192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-RGD-PET-CT and perfusion CT scans on 3 occasions
Description: Fluciclatide (GE Healthcare) (AH111585) is a small cyclic peptide containing the RGD tripeptide (figure 1), which preferentially binds with high affinity to α¬vβ3 integrins that are up-regulated in angiogenesis.~The IMP is supplied as a solution for injection, 400 MBq at the reference date and time. Participants will receive one injection of the imaging agent at this dose on 3 occasions
Study NCT00866112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational session to promote physical activity
Description: Educational session, goal setting, self monitoring of daily engagement in physical activity
Study NCT00866112 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Minimal contact
Description: Self guided education manual about adopting physical activity, self monitor daily engagement in physical activity
Study NCT02893046 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT01337817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ariva Silver Wintergreen
Description: Study product containing 6 mg silver salt and 2 mg nicotine per dissolvable lozenge, administered orally as a single dose.
Study NCT01337817 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ariva Wintergreen
Description: Comparator product, a compressed dissolvable smokeless tobacco lozenge containing 2 mg nicotine administered orally as a single dose.
Study NCT01822210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: injection by gastroscopy (100 Allergen units)
Study NCT02382315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fear of Cancer Recurrence Intervention
Description: A 6-week individual therapy intervention to address fear of cancer recurrence in male and female cancer survivors. Patients will learn tools and techniques to help manage their fears, and learn to tolerate the uncertainty associated with the possibility of their cancer recurring.
Study NCT02797977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRA737, gemcitabine, cisplatin
Study NCT02797977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRA737, gemcitabine
Study NCT03603119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline, Midazolam
Description: 2 cc normal saline i.v. after anaesthesia induction.2 mg of injection midazolam intravenous 30 minutes prior to the end of surgery
Study NCT03603119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone, ondansetron
Description: 8mg of dexamethasone i.v. after anaesthesia induction and 4 mg of ondansetron i.v. 30 minutes prior to the end of surgery.
Study NCT03065387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO
Study NCT03065387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Given PO
Study NCT03065387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study NCT03065387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study NCT03446040 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986258
Description: Specified dose on specified days
Study NCT02499120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palbociclib
Description: Palbociclib will be supplied as capsules containing 75 mg, 100 mg, or 125 mg equivalents of palbociclib free base. Administered with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle.
Study NCT02499120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab injection for IV infusion will be provided in 100 mg/50 mL, single-use vials, and 200 mg/100 mL, single-use vials. In Japan, cetuximab will be provided in 100 mg/20 mL, single-use vials. Administered, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.
Study NCT02499120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab injection for IV infusion will be provided in 100 mg/50 mL, single-use vials, and 200 mg/100 mL, single-use vials. In Japan, cetuximab will be provided in 100 mg/20 mL, single-use vials. Administered, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.
Study NCT02499120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for palbociclib will be indistinguishable from the palbociclib capsules and will be supplied as capsules matching in size and color the various palbociclib formulations.~Administered with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle.
Study NCT01973426 — intervention group
Intervention type: DEVICE
Intervention: Isolated Orthosis for Thumb Actuation (IOTA)
Description: In this pilot study, we plan to investigate whether the IOTA can effectively facilitate the ability of participants to perform a specific set of clinically relevant tasks conducted in a clinic setting. The IOTA is a device developed at the Wyss Institute at Harvard University, in collaboration with Children's Hospital Boston, for assisting opposable thumb grasping tasks. The IOTA contains an adjustable brace fitted to the thumb and dorsum of the hand that is easy to put on and facilitates grasping motions through flexible cable-driven actuators that assist with joint abduction and extension.
Study NCT00952315 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cyberwand
Description: Dual probe lithotrite Cyberwand will be used to remove kidney stone. Duration will be timed and documented.
Study NCT00952315 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stonebreaker
Description: Stonebreaker will be used to break up the kidney stone. Duration will be timed and documented.
Study NCT00952315 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lithoclast Select
Description: Lithoclast Select will be used to break up and remove the kidney stone. Duration will be timed and documented
Study NCT02377232 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Decision Aid for Colon Cancer Screening
Description: Paper decision aid describing different screening options for colon cancer
Study NCT02377232 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Outreach for Colon Cancer Screening
Description: Patients overdue for colon cancer screening are contacted and outreach is performed in an effort to schedule colonoscopy
Study NCT01377636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoproterenol
Description: patients will receive isoproterenol, have a BIS monitoring device and a modified isolated forearm test (no neuromuscular blockade).
Study NCT00767598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phosphodiesterase type 5 inhibitor
Description: single oral administration of 20mg vardenafil
Study NCT00767598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phosphodiesterase type 5 inhibitor
Description: single oral administration of 100mg sildenafil
Study NCT03446040 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT03446040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: Specified dose on specified days
Study NCT00977977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab Infusion
Description: Drug Rituximab Infusion 2 infusions (each 1000 mg) separated by 2 weeks; repeated after 6 months
Study NCT00977977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Cyclosporine
Description: Daily therapy for 6 months (3-5 mg/kg), then tapered and discontinued
Study NCT00767598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phosphodiesterase type 5 inhibitor
Description: single oral administration of 200mg udenafil
Study NCT01739504 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction with Local Anesthesia
Description: Liposuction under tumescent anesthesia for adipose tissue harvesting.
Study NCT01739504 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intra articular infusion of AD-SVF
Description: Adipose tissue is available in most patients for harvest through minimally invasive procedures such as liposuction. AD-SVF can be obtained in large quantities after processing of adipose tissue in the laboratory.~* AD-SVF to promote tissue regeneration and repair with their ability to secrete various growth factors that can modulate host tissue environment.~* Patient's AD-SVF combined with PRP are used for direct intra-articular injection after processing.
Study NCT01941199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229
Study NCT01941199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Study NCT01941199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229 + metformin
Study NCT01494012 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Undergo SBRT
Study NCT01494012 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo FDG-PET/CT
Study NCT01494012 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo FDG-PET/CT
Study NCT01494012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01494012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Undergo FDG-PET/CT
Study NCT01719159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 25 mg rituximab is injected intrathecally via an Ommaya reservoir once a week for 3 weeks. Patients are then followed for one year.
Study NCT02472262 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cow pea complementary food
Description: A legume-based complementary food made from cowpeas will be given for 6 months, 200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
Study NCT02472262 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Corn soy flour
Description: Corn flour with 10% soy will be given for 6 months, 200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
Study NCT02472262 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Common bean
Description: A legume-based complementary food made from common beans will be given for 6 months,200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
Study NCT04442477 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Enriched Protein Fractions
Description: Enriched protein fractions
Study NCT04442477 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Protein Fraction
Description: Protein fractions
Study NCT02963636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist clinical intervention
Description: Pharmacists will make a clinical intervention with patients. They will review patient drug therapy already prescribed in their usual care. This includes a medication reconciliation, an assessment of drug related problems, an assessment of the regimen complexity and adherence to treatment. A care plan will be elaborated. Moreover, immediate and future interventions with the patient or other health professionals will be implemented and monitored. There will be no drug or devices tested, it is a human clinical intervention by a pharmacist.
Study NCT04162795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine (Claritin, BAY76-2211)
Description: Chewable tablet, oral, single dose
Study NCT03939533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUTAQUIG
Description: Human normal immunoglobulin
Study NCT02506062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual blood pressure cuff inflation over brachial artery
Description: A manual blood pressure cuff (sphygmomanometer) is used in the study as a tourniquet in order to perform a controlled, consistent level of ischemia (200mmHg/active arm or 60 mmHg/placebo arm).
Study NCT02506062 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Manual blood pressure cuff inflation over brachial artery
Description: A manual blood pressure cuff (sphygmomanometer) is used in the study as a tourniquet in order to perform a controlled, consistent level of ischemia (200mmHg/active arm or 60 mmHg/placebo arm).
Study NCT03429621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simethicone 80 MG
Description: Simethicone (Air-X®; 80 mg) 2 tablets chewing with water 50 ml at 2-8 hours before surgery
Study NCT02527174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Description: Addition of single dose of volasertib intravenously (IV) on Day 4 of treatment protocol.
Study NCT02527174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV daily on Days 1-3 of treatment protocol.
Study NCT02527174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV daily as 24-hour continuous infusion on Day 1-7 of treatment protocol.
Study NCT02248168 — intervention group
Intervention type: DRUG
Intervention: Pramipexole
Study NCT04602156 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trocar percutaneous cholecystostomy
Description: Percutaneous cholecystostomy using the one-step Trocar technique under US guidance. An 8Fr Trocar catheter will be inserted percutaneously within the gallbladder under real-time US guidance. The procedure will be performed using an aseptic technique, local anesthesia and intravenous opioid analgesia.
Study NCT04602156 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Seldinger percutaneous cholecystostomy
Description: Percutaneous cholecystostomy using the Seldinger technique under US guidance. Following percutaneous puncture of the gallbladder with an 18G needle under real-time US guidance, an 8Fr catheter will be inserted percutaneously over the wire within the gallbladder under real-time US guidance. The procedure will be performed using an aseptic technique, local anesthesia and intravenous opioid analgesia.
Study NCT00523692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept, methotrexate and depomedrone
Description: Etanercept (50mg weekly; subcutaneous) Methotrexate (7.5-25mg weekly; oral) Depomedrone (up to 120mg; intraarticular / intramuscular)
Study NCT00523692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: depemedrone
Description: depomedrone (up to 120mg im/ia) methotrexate (added after symptoms have been present for 12 weeks)
Study NCT04570709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative And supportive Care inTervention (PACT)
Description: Using the Adaptive Leadership Framework for Chronic Illness as a guide. The nurse, occupational and physical therapists will meet with the patient and caregiver after the baseline assessment to discuss their Specific, Measurable, Achievable, Relevant, and Time-Bound (SMART) goals. Additionally, the occupational and physical therapists will provide the patient a PACT intervention binder. Regular phone calls or visits from a registered nurse, occupational therapists, and physical therapists for patients and caregivers in the intervention.
Study NCT02049983 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of Levita Magnetics Grasper
Study NCT02675270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phonological
Description: This treatment involves picture viewing and word repetition.
Study NCT02675270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Orthographic
Description: This treatment involves picture viewing, reading, and writing.
Study NCT02675270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Semantic
Description: This treatment involves learning about the semantic features (meaning) of each trained word.
Study NCT02675270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lexical
Description: This treatment involves learning about the lexical features (letters and sounds) of each trained word.
Study NCT02675270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Untrained
Description: These words are not trained during the treatment phase.
Study NCT04069143 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-BMS-986327
Description: Imaging Agent
Study NCT02664064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevent
Description: Intensive behavioral counseling for diabetes prevention and healthy lifestyle management. Recipients have access to online curriculum, a live health coach, group-based communication forums, and connected technology to track weight and physical activity.
Study NCT02076347 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Office visit intervention
Description: Pharmacist communicates monitoring recommendations to physician through the electronic medical record prior to a scheduled patient office visit
Study NCT02076347 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Message Intervention
Description: Pharmacist communicates need for monitoring directly to patients and instructs them to obtain monitoring on their own time without need for an office visit with physician
Study NCT02961387 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrogen generator treatment
Description: The patients mainly used the hydrogen generator with nebulizer for inhalation of hydrogen-oxygen mixed gas.
Study NCT02961387 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Hydrogen generator treatment
Description: The patients mainly used the hydrogen generator with nebulizer for inhalation of hydrogen-oxygen mixed gas.
Study NCT02961387 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen-making machine treatment
Description: The patients mainly used medical molecular sieve oxygen-making machine for oxygen inhalation.
Study NCT02961387 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Oxygen-making machine treatment
Description: The patients mainly used medical molecular sieve oxygen-making machine for oxygen inhalation.
Study NCT03364036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavenclad®
Description: Participants received Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
Study NCT05240703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stabilization splint treatment
Description: The stabilization splints were made of heat-cured acrylic by the same dental technician. The occlusion of the splint was defined in the centric relation occlusion using wax (Astynax, Associated Dental Products Ltd, UK). The patients were instructed to use the splint every night during the course of the study. The patients were instructed to perform a standardized program for masticatory muscle exercises. At the beginning of the training program, active mouth openings, laterotrusive movements and protrusive movements were performed. The mandible was held in the maximal positions for a few seconds on each movement. Thereafter, these movements were made towards resistance (using the patient's own fingers). After jaw exercises, the patients were suggested to open the jaw wide, stretching it with fingers a few times for 10 to 20 seconds. These movements were repeated 7 to 10 times per training session, and the sessions were performed 2-3 times per day.